{"id":202175,"date":"2026-08-13T16:06:06","date_gmt":"2026-08-13T10:36:06","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=202175"},"modified":"2026-08-13T16:06:07","modified_gmt":"2026-08-13T10:36:07","slug":"jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/","title":{"rendered":"Jagsonpal Pharmaceuticals Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Jagsonpal Pharmaceuticals analyst target 2027: Rs 179 (-20%). 2028: Rs 210. Long-term target 2030: Rs 280 (+25%). CMP Rs 224.31.<\/em><\/p>\n<div style=\"background: #F0F9FF; border-left: 4px solid #2E7D32; border-radius: 6px; padding: 14px 18px; margin: 18px 0;\">\n<p style=\"margin: 0; color: #1f4e79; font-size: 14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin: 8px 0 0;\">The Jagsonpal Pharmaceuticals share price target for 2027 is Rs 179, which sits around 20 percent below the current price of Rs 224.31. Analysts expect a stronger recovery from 2028, with the target rising to Rs 210 before reaching Rs 280 by 2030 , a potential gain of approximately 25 percent from today&#8217;s levels. FY26 EPS of \u20b96.4 growing approximately16% a year, capitalised at approximately24x forward earnings; growth tapers to app. Investors considering Jagsonpal Pharmaceuticals should weigh the 2030 upside case against the near-term consolidation phase and the sector-specific risks outlined below.<\/p>\n<\/div>\n<p>Jagsonpal Pharmaceuticals is trading at Rs 224.31 with near-term consolidation expected , the 2027 target of Rs 179 is approximately 20 percent below the current price. The more compelling case is in the outer years , Rs 210 by 2028 and Rs 280 by 2030 , as the earnings model builds toward that trajectory. FY26 EPS of \u20b96.4 growing approximately16% a year, capitalised at approximately24x forward earnings; growth tapers to approximately13% further out.<\/p>\n<p>This article breaks down the Jagsonpal Pharmaceuticals share price target for 2027, 2028, and 2030, the sector-specific drivers behind the analyst model, and the risks that could delay or derail the forecast.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=jagsonpal-pharmaceuticals-spt\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#Jagsonpal_Pharmaceuticals_Company_Overview_and_Share_Price_Target_Summary\" title=\"Jagsonpal Pharmaceuticals Company Overview and Share Price Target Summary\">Jagsonpal Pharmaceuticals Company Overview and Share Price Target Summary<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#Why_Analysts_Have_Set_the_Jagsonpal_Pharmaceuticals_share_price_target_at_Rs_179_for_2027\" title=\"Why Analysts Have Set the Jagsonpal Pharmaceuticals share price target at Rs 179 for 2027\">Why Analysts Have Set the Jagsonpal Pharmaceuticals share price target at Rs 179 for 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#Domestic_Formulations_Revenue_Is_Growing_Ahead_of_Sector\" title=\"Domestic Formulations Revenue Is Growing Ahead of Sector\">Domestic Formulations Revenue Is Growing Ahead of Sector<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#Export_Markets_and_Regulatory_Compliance_Give_Revenue_Visibility\" title=\"Export Markets and Regulatory Compliance Give Revenue Visibility\">Export Markets and Regulatory Compliance Give Revenue Visibility<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#New_Product_Approvals_Will_Drive_the_Next_Leg_of_Growth\" title=\"New Product Approvals Will Drive the Next Leg of Growth\">New Product Approvals Will Drive the Next Leg of Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#Manufacturing_Scale_Keeps_Cost_Structures_Competitive\" title=\"Manufacturing Scale Keeps Cost Structures Competitive\">Manufacturing Scale Keeps Cost Structures Competitive<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#Indias_Healthcare_Spending_Is_Compounding_at_Above-GDP_Rates\" title=\"India&#8217;s Healthcare Spending Is Compounding at Above-GDP Rates\">India&#8217;s Healthcare Spending Is Compounding at Above-GDP Rates<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#Jagsonpal_Pharmaceuticals_Share_Price_Target_2027_2028_and_2030_Year-Wise_Breakdown\" title=\"Jagsonpal Pharmaceuticals Share Price Target 2027, 2028 and 2030: Year-Wise Breakdown\">Jagsonpal Pharmaceuticals Share Price Target 2027, 2028 and 2030: Year-Wise Breakdown<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#2027_Target_Rs_179\" title=\"2027 Target: Rs 179\">2027 Target: Rs 179<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#2028_Target_Rs_210\" title=\"2028 Target: Rs 210\">2028 Target: Rs 210<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#2030_Target_Rs_280\" title=\"2030 Target: Rs 280\">2030 Target: Rs 280<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#Bull_Case_and_Bear_Case_for_Jagsonpal_Pharmaceuticals_by_2030\" title=\"Bull Case and Bear Case for Jagsonpal Pharmaceuticals by 2030\">Bull Case and Bear Case for Jagsonpal Pharmaceuticals by 2030<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#Bull_Case_Rs_358\" title=\"Bull Case: Rs 358\">Bull Case: Rs 358<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#Bear_Case_Rs_210\" title=\"Bear Case: Rs 210\">Bear Case: Rs 210<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#Key_Risks_to_the_Jagsonpal_Pharmaceuticals_Forecast\" title=\"Key Risks to the Jagsonpal Pharmaceuticals Forecast\">Key Risks to the Jagsonpal Pharmaceuticals Forecast<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#Regulatory_Risk\" title=\"Regulatory Risk\">Regulatory Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#Currency_Headwind\" title=\"Currency Headwind\">Currency Headwind<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#Generic_Pricing_Pressure\" title=\"Generic Pricing Pressure\">Generic Pricing Pressure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#Pipeline_Delays\" title=\"Pipeline Delays\">Pipeline Delays<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#How_to_Invest_in_Jagsonpal_Pharmaceuticals\" title=\"How to Invest in Jagsonpal Pharmaceuticals\">How to Invest in Jagsonpal Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#Frequently_Asked_Questions_on_Jagsonpal_Pharmaceuticals_Share_Price_Target_2027_2028_and_2030\" title=\"Frequently Asked Questions on Jagsonpal Pharmaceuticals Share Price Target 2027 2028 and 2030\">Frequently Asked Questions on Jagsonpal Pharmaceuticals Share Price Target 2027 2028 and 2030<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#What_is_the_Jagsonpal_Pharmaceuticals_share_price_target_for_2027\" title=\"What is the Jagsonpal Pharmaceuticals share price target for 2027?\">What is the Jagsonpal Pharmaceuticals share price target for 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#What_is_the_Jagsonpal_Pharmaceuticals_share_price_target_for_2030\" title=\"What is the Jagsonpal Pharmaceuticals share price target for 2030?\">What is the Jagsonpal Pharmaceuticals share price target for 2030?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#What_is_the_Jagsonpal_Pharmaceuticals_share_price_target_for_2028\" title=\"What is the Jagsonpal Pharmaceuticals share price target for 2028?\">What is the Jagsonpal Pharmaceuticals share price target for 2028?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#Is_Jagsonpal_Pharmaceuticals_a_good_long-term_investment\" title=\"Is Jagsonpal Pharmaceuticals a good long-term investment?\">Is Jagsonpal Pharmaceuticals a good long-term investment?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#What_are_the_key_risks_to_the_Jagsonpal_Pharmaceuticals_analyst_forecast\" title=\"What are the key risks to the Jagsonpal Pharmaceuticals analyst forecast?\">What are the key risks to the Jagsonpal Pharmaceuticals analyst forecast?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#What_is_the_bull_case_for_Jagsonpal_Pharmaceuticals_by_2030\" title=\"What is the bull case for Jagsonpal Pharmaceuticals by 2030?\">What is the bull case for Jagsonpal Pharmaceuticals by 2030?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#What_sector_does_Jagsonpal_Pharmaceuticals_belong_to\" title=\"What sector does Jagsonpal Pharmaceuticals belong to?\">What sector does Jagsonpal Pharmaceuticals belong to?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030\/#How_can_I_track_and_invest_in_Jagsonpal_Pharmaceuticals\" title=\"How can I track and invest in Jagsonpal Pharmaceuticals?\">How can I track and invest in Jagsonpal Pharmaceuticals?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Jagsonpal_Pharmaceuticals_Company_Overview_and_Share_Price_Target_Summary\"><\/span><strong>Jagsonpal Pharmaceuticals Company Overview and Share Price Target Summary<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse: collapse; width: 100%; margin: 16px 0;\">\n<tbody>\n<tr style=\"background: #1F4E79; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Metric<\/th>\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Details<\/th>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">NSE Ticker<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">JAGSNPHARM<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Sector<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Pharma and Healthcare<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">CMP (13 Aug 2026)<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 224.31<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Market Cap<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 1476 Cr<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Jagsonpal Pharmaceuticals Share Price Target 2027<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 179 (-20%)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Jagsonpal Pharmaceuticals Share Price Target 2028<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 210 (-6%)<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Jagsonpal Pharmaceuticals Share Price Target 2030<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 280 (+25%)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bull Case 2030<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 358<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bear Case 2030<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 210<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"border-left: 4px solid #e67e22; background: #FEF9F0; padding: 10px 16px;\"><strong>What most investors miss about Jagsonpal Pharmaceuticals:<\/strong> Completed acquisition of 77.21% stake in Aequitas Healthcare on July 8, 2026, a fresh inorganic growth catalyst<\/p>\n<p>FY26 EPS of \u20b96.4 growing approximately16% a year, capitalised at approximately24x forward earnings; growth tapers to approximately13% further out..<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Analysts_Have_Set_the_Jagsonpal_Pharmaceuticals_share_price_target_at_Rs_179_for_2027\"><\/span><strong>Why Analysts Have Set the Jagsonpal Pharmaceuticals share price target at Rs 179 for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Domestic_Formulations_Revenue_Is_Growing_Ahead_of_Sector\"><\/span><strong>Domestic Formulations Revenue Is Growing Ahead of Sector<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This is the clearest reason the analyst model converges on Rs 280 by 2030. FY26 EPS of \u20b96.4 growing approximately16% a year, capitalised at approximately24x forward earnings; growth tapers to app. Tracking this factor quarterly gives the earliest signal on whether the long-term analyst target stays on course.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Export_Markets_and_Regulatory_Compliance_Give_Revenue_Visibility\"><\/span><strong>Export Markets and Regulatory Compliance Give Revenue Visibility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Jagsonpal Pharmaceuticals share price target for 2028 , Rs 210 , is built partly on this continuing to hold. If it deteriorates, the timeline for the outer-year forecast extends, not the target itself. Investors should track it with every results cycle.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"New_Product_Approvals_Will_Drive_the_Next_Leg_of_Growth\"><\/span><strong>New Product Approvals Will Drive the Next Leg of Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This underpins Jagsonpal Pharmaceuticals&#8217;s growth beyond the 2027 near-term. It is the kind of durable structural factor that keeps analysts positive on the 2030 target even when quarterly numbers disappoint.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Manufacturing_Scale_Keeps_Cost_Structures_Competitive\"><\/span><strong>Manufacturing Scale Keeps Cost Structures Competitive<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>For the 2028 recovery thesis to work, Jagsonpal Pharmaceuticals needs to maintain consistency here. One cycle of weakness would not break the long-term case, but two consecutive quarters of deterioration would prompt downgrades.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Indias_Healthcare_Spending_Is_Compounding_at_Above-GDP_Rates\"><\/span><strong>India&#8217;s Healthcare Spending Is Compounding at Above-GDP Rates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This is the macro layer that most company-specific screens miss. It amplifies Jagsonpal Pharmaceuticals&#8217;s own earnings compounding and is why analysts are more constructive on the 2030 horizon than on 2027.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Jagsonpal_Pharmaceuticals_Share_Price_Target_2027_2028_and_2030_Year-Wise_Breakdown\"><\/span><strong>Jagsonpal Pharmaceuticals Share Price Target 2027, 2028 and 2030: Year-Wise Breakdown<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"2027_Target_Rs_179\"><\/span><strong>2027 Target: Rs 179<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Rs 179 is the 2027 analyst target, implying near-term consolidation expected , the 2027 target of Rs 179 is approximately 20 percent below the current price. At this level, Jagsonpal Pharmaceuticals would be trading on forward multiples consistent with the current earnings trajectory. The 2027 milestone is essentially a staging post , confirmed only after two to three quarters of on-track delivery.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2028_Target_Rs_210\"><\/span><strong>2028 Target: Rs 210<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Rs 210 is where analysts see Jagsonpal Pharmaceuticals by 2028, roughly -6 percent above today&#8217;s price. By FY29, the business should have moved past the near-term consolidation, and the Jagsonpal Pharmaceuticals share price target for 2028 typically re-rates faster than markets initially expect once the earnings inflection becomes visible.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2030_Target_Rs_280\"><\/span><strong>2030 Target: Rs 280<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The long-term case is Rs 280 by 2030 , a potential gain of approximately 25 percent from CMP Rs 224.31, which works out to a 4-year CAGR of roughly 6 percent. By FY31, Jagsonpal Pharmaceuticals should be operating at a scale and earnings quality that justifies the multiple implied by this target. Please verify all data at NSE and BSE before making any investment decision.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Bear_Case_for_Jagsonpal_Pharmaceuticals_by_2030\"><\/span><strong>Bull Case and Bear Case for Jagsonpal Pharmaceuticals by 2030<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Rs_358\"><\/span><strong>Bull Case: Rs 358<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bull case lands at Rs 358 by 2030. This requires better-than-expected earnings growth alongside a re-rating of the multiple , both need to land together. Favourable macro conditions, new business wins, or a sector re-rating could drive this scenario without needing extraordinary operational delivery from the company.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Bear_Case_Rs_210\"><\/span><strong>Bear Case: Rs 210<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bear case is Rs 210 by 2030 , still above today&#8217;s price in most scenarios, but a significantly slower path. This applies if earnings miss across FY27 to FY28, competitive pressure intensifies, or a macro slowdown compresses sector multiples before Jagsonpal Pharmaceuticals can re-rate upward.<\/p>\n<table style=\"border-collapse: collapse; width: 100%; margin: 16px 0;\">\n<tbody>\n<tr style=\"background: #1F4E79; color: #fff;\">\n<th style=\"padding: 8px 12px; border: 1px solid #ddd;\">Scenario<\/th>\n<th style=\"padding: 8px 12px; border: 1px solid #ddd;\">Target 2030<\/th>\n<th style=\"padding: 8px 12px; border: 1px solid #ddd;\">Return<\/th>\n<th style=\"padding: 8px 12px; border: 1px solid #ddd;\">Key Assumption<\/th>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bull Case<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 358<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">+60%<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Above-consensus growth; multiple expansion<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Base Case<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 280<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">+25%<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Base-case CAGR; peer multiples hold<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bear Case<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 210<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">-6%<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Earnings miss; macro pressure; multiple contraction<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Jagsonpal_Pharmaceuticals_Forecast\"><\/span><strong>Key Risks to the Jagsonpal Pharmaceuticals Forecast<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Regulatory_Risk\"><\/span><strong>Regulatory Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A USFDA warning letter or facility import alert would delay US launches and compress the export revenue that drives the outer-year targets.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Currency_Headwind\"><\/span><strong>Currency Headwind<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>INR appreciation against USD reduces the INR value of Jagsonpal Pharmaceuticals&#8217;s foreign revenue without any change in business performance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Generic_Pricing_Pressure\"><\/span><strong>Generic Pricing Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Pricing erosion in US generic markets, especially in key molecules, can shrink EBITDA margins faster than volume growth compensates.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Pipeline_Delays\"><\/span><strong>Pipeline Delays<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Clinical or regulatory delays in new product filings push revenue ramp timelines, affecting the 2028 and 2030 targets specifically.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Jagsonpal_Pharmaceuticals\"><\/span><strong>How to Invest in Jagsonpal Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Start by tracking Jagsonpal Pharmaceuticals&#8217;s quarterly results against the model assumptions. The Univest Screener gives you live fundamentals, analyst upgrade history, and price alerts on NSE ticker JAGSNPHARM , the same data points that drive the Jagsonpal Pharmaceuticals share price target model. Build positions in tranches across the 2027 to 2028 window rather than committing fully now, and consult a SEBI-registered financial advisor before investing.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Track This Stock Live on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Jagsonpal Pharmaceuticals share price target of Rs 179 for 2027, Rs 210 for 2028, and Rs 280 for 2030 reflects the analyst model built on Jagsonpal Pharmaceuticals&#8217;s earnings trajectory in the pharma and healthcare sector. The near-term picture is one of consolidation; the case for patient investors is in the 2028 to 2030 window. Always verify financial data at NSE India and BSE India before making any investment decision.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Jagsonpal Pharmaceuticals share price live and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Jagsonpal_Pharmaceuticals_Share_Price_Target_2027_2028_and_2030\"><\/span><strong>Frequently Asked Questions on Jagsonpal Pharmaceuticals Share Price Target 2027 2028 and 2030<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Jagsonpal_Pharmaceuticals_share_price_target_for_2027\"><\/span><strong>What is the Jagsonpal Pharmaceuticals share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Jagsonpal Pharmaceuticals share price target for 2027 is Rs 179, which is approximately 20 percent slightly below the current market price of Rs 224.31. This near-term target reflects the analyst consensus as of August 2026. Verify all data at NSE India before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Jagsonpal_Pharmaceuticals_share_price_target_for_2030\"><\/span><strong>What is the Jagsonpal Pharmaceuticals share price target for 2030?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 2030 analyst target for Jagsonpal Pharmaceuticals is Rs 280, implying approximately 25 percent potential upside from CMP Rs 224.31. This is the base-case extrapolation from the current earnings growth model. These are analyst estimates and not guaranteed returns.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Jagsonpal_Pharmaceuticals_share_price_target_for_2028\"><\/span><strong>What is the Jagsonpal Pharmaceuticals share price target for 2028?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Jagsonpal Pharmaceuticals share price target for 2028 is Rs 210, approximately -6 percent from the current price. By FY29, the business should be past the near-term consolidation phase, which makes the 2028 target more realistically achievable than the 2027 level.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Jagsonpal_Pharmaceuticals_a_good_long-term_investment\"><\/span><strong>Is Jagsonpal Pharmaceuticals a good long-term investment?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Jagsonpal Pharmaceuticals has a defined earnings growth thesis in the pharma and healthcare sector, with targets that project meaningful upside by 2030. Whether it suits your portfolio depends on your risk appetite, investment horizon, and current allocation. Speak with a SEBI-registered financial advisor before deciding.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_to_the_Jagsonpal_Pharmaceuticals_analyst_forecast\"><\/span><strong>What are the key risks to the Jagsonpal Pharmaceuticals analyst forecast?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The most significant risks are regulatory risk and currency headwind. Beyond these, broader macro slowdowns and sector-specific headwinds can compress multiples even when the company itself is executing well.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_bull_case_for_Jagsonpal_Pharmaceuticals_by_2030\"><\/span><strong>What is the bull case for Jagsonpal Pharmaceuticals by 2030?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The bull case target is Rs 358 by 2030. This requires above-consensus earnings growth and a re-rating of the PE multiple , both need to happen together. These are analyst projections, not guaranteed outcomes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_sector_does_Jagsonpal_Pharmaceuticals_belong_to\"><\/span><strong>What sector does Jagsonpal Pharmaceuticals belong to?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Jagsonpal Pharmaceuticals operates in the pharma and healthcare sector. This sector classification influences the peer multiples applied in the analyst target model and the macro factors that most directly affect the company&#8217;s earnings outlook.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_can_I_track_and_invest_in_Jagsonpal_Pharmaceuticals\"><\/span><strong>How can I track and invest in Jagsonpal Pharmaceuticals?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> You can buy Jagsonpal Pharmaceuticals shares through any SEBI-registered broker using NSE ticker JAGSNPHARM. The Univest Screener lets you track live fundamentals, set price alerts, and monitor analyst ratings. Always consult a SEBI-registered financial advisor before investing.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jagsonpal Pharmaceuticals share price target 2027 is Rs 179 (-20%), 2028 is Rs 210 (-6%), and 2030 is Rs 280 (+25%). Pharma and Healthcare stock long term analyst forecas<\/p>\n","protected":false},"author":35,"featured_media":202174,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[3802],"class_list":["post-202175","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["202174"],"rank_math_title":["Jagsonpal Pharmaceuticals Share Price Target 2027, 2028 and"],"rank_math_description":["Jagsonpal Pharmaceuticals share price target 2027 is Rs 179 (-20%), 2028 is Rs 210 (-6%), and 2030 is Rs 280 (+25%). Pharma and Healthcare stock long term"],"rank_math_focus_keyword":["jagsonpal pharmaceuticals share price target"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_lock":["1786617373:29"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["24"],"rank_math_seo_score":["79"],"_edit_last":["29"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["36983"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/jagsonpal-pharmaceuticals-share-price-target-2027-2028-2030.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/202175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=202175"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/202175\/revisions"}],"predecessor-version":[{"id":202184,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/202175\/revisions\/202184"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/202174"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=202175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=202175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=202175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}